Creating Better Medicines Through Scientific Innovation
Pet Pharmaceuticals is a pharmaceutical company pioneering a new therapeutic class of pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines.
About Pet Pharmaceuticals
Our mission is to unlock nature’s therapeutic potential through rigorous pharmaceutical science, creating safer, more effective medicines that address important unmet clinical needs.
Advances in pharmaceutical science now make it possible to harness the therapeutic diversity of nature in ways that were previously beyond reach. By combining modern drug discovery with carefully designed multi-pathway combination medicines, we aim to create differentiated prescription medicines for chronic and complex diseases.
Our Purpose
Our purpose is simple:
To transform nature’s therapeutic potential into pharmaceutical reality by creating safer, more effective medicines.
To transform nature’s therapeutic potential into pharmaceutical reality by creating safer, more effective medicines.
Everything we do is guided by this objective—from scientific discovery and pharmaceutical development to strategic partnerships and long-term value creation.
Our Scientific Philosophy
Much of modern pharmaceutical innovation has focused on developing medicines that act on individual biological targets. While this approach has delivered significant advances, many chronic and complex diseases involve multiple interconnected biological pathways.
We believe these diseases require a broader therapeutic approach.
Pet Pharmaceuticals is pioneering pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines, bringing together carefully selected combinations of naturally occurring bioactive compounds with rigorous pharmaceutical science.
Our objective is to develop medicines designed to address disease biology more comprehensively while maintaining rigorous standards of pharmaceutical quality, safety, consistency and scientific validation.
Our Integrated Scientific Discovery Capability
Innovation at Pet Pharmaceuticals is driven by our Integrated Scientific Discovery Capability, which combines pharmaceutical science, natural-product research, proprietary scientific knowledge and advanced analytical technologies to identify, optimise and develop differentiated pharmaceutical assets.
Within this capability, our proprietary PolyNexis+™ Discovery Platform supports candidate identification, optimisation and scientific decision-making. AI and advanced data science act as enabling technologies within this process, strengthening discovery while remaining one component of our broader scientific capability.
Our Focus
Our immediate priority is companion animal medicine, where significant unmet clinical needs, attractive development timelines and strong commercial dynamics provide an exceptional opportunity to create value.
Our initial therapeutic portfolio addresses six important disease areas:
Parasiticides
Osteoarthritis
Dermatitis
Oncology (Lymphoma)
Diabetes / Obesity
Anxiety
Together, these programmes demonstrate the breadth and scalability of our scientific capability while creating multiple opportunities for future innovation and value creation.
Our Vision
We aspire to establish Pet Pharmaceuticals as a global leader in pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines, delivering innovative therapies that improve health and wellbeing.
Our immediate focus remains companion animal medicine. Over time, the scientific capability we are building has the potential to extend into livestock health and, ultimately, selected human therapeutic applications.
Our One Health Philosophy
Pet Pharmaceuticals recognises the close relationship between animal health, human health and the environment.
By combining rigorous pharmaceutical science with responsible sourcing and sustainable innovation, we aim to develop medicines that support healthier animals while contributing to the wider principles of One Health.
Our work begins in companion animal medicine, but the scientific knowledge and therapeutic capability we are building may have broader relevance across animal and human health over time.
Leadership
Pet Pharmaceuticals is led by a world-class Board of Directors, supported by an internationally recognised Scientific & Strategic Advisory Board.
Together, they bring extensive expertise across pharmaceutical research and development, veterinary medicine, regulatory science, health economics, market access, commercial strategy and corporate leadership.
Their collective experience strengthens the Company’s scientific governance, strategic direction and ability to create long-term value.
Our Mission
Our mission is to become the global leader in prescription veterinary phytopharmaceuticals through the combination of:
Artificial intelligence
Pharmaceutical Science
Veterinary Medicine
Clinical Research
Regulatory Excellence
Our proprietary discovery platform, PolyNexis+™, enables the identification and optimisation of novel multi-compound therapeutics designed to address significant unmet needs in animal health.
Unlike traditional veterinary supplements or wellness products, our focus is on the development of regulatory-approved prescription medicines suitable for inclusion within veterinary prescribing pathways.
Our Vision
To become the preferred innovation partner for the global animal health industry through the development of next-generation veterinary therapeutics.
The Principles That Guide Us
Scientific Rigour
Every discovery is expected to meet the standards required for pharmaceutical development.
Better Medicines
We pursue innovative therapeutic approaches designed to create safer, more effective medicines for chronic and complex diseases.
Responsible Innovation
We combine scientific ambition with ethical research, responsible sourcing and disciplined pharmaceutical development.
Long-Term Impact
We are building a sustainable scientific capability designed to create lasting value for companion animals, future therapeutic applications and our partners.